2025 Q4 -tulosraportti
Vain PDF
92 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sittenA bit of pure speculation, but I find the timing interesting. Ivan Krivega announced today that he is leaving SonoThera. He has a strong background from SonoThera, Sangamo, BioMarin, and NIH, with a main focus on AAV, gene therapy, and delivery platforms. That made me think of some possible connections. Sangamo and Eli Lilly entered into a collaboration on STAC-BBB, an AAV platform for CNS delivery. Around the same period, Circio announced a fully funded feasibility program with an unnamed top-5 pharmaceutical partner within circVec + AAV for a CNS indication. SonoThera is simultaneously developing RIPPLE™, a non-viral delivery platform based on ultrasound (sonoporation), while Circio is developing circVec, which is a platform for more efficient and long-lasting gene expression. Technologically, these seem more complementary than competitive – one focuses on delivery, the other on expression. Circio has already shown that they want to test circVec with several different delivery systems through collaborations with, among others, Acuitas, GenAssist, TraffikGene, and an unknown top-5 pharma. Therefore, it is not unthinkable that other delivery companies could also be interesting in the long term. Is there a connection between Circio, SonoThera, Sangamo, and Lilly? There is no public information to suggest it. This is purely speculation. But when one sees how much activity is happening around CNS, AAV, circRNA, and new delivery platforms, it seems that many of the same players are moving in the same technological landscape. It will be exciting to see what collaborations emerge in the next 12–24 months. https://www.linkedin.com/posts/ikrivega_today-marks-my-last-day-with-sonothera-share-7483185910994468864-2GIX/?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyU
In his time at Sangamo, he was involved with: In vivo genome editing. AAV-based gene therapy. Optimization of gene expression. Delivery of genetic material to organs, including CNS programs. Sangamo's blood-brain barrier capsids which Eli Lilly licensed. He is also listed as an inventor on several Sangamo patents within genome engineering and gene editing. See attached.
·10 t sitten · MuokattuNow 3 months ago to the day - 15. April the announcement with Acuitas came. Levitsky stated here translated from the announcement: "Acuitas has developed a state-of-the-art LNP delivery platform specifically to deliver Circio's circVec constructs into T-cells. By combining circVec technology's unparalleled expression durability with the precision of delivery from Acuitas’ LNPs, we aim to establish a new in vivo CAR-T concept for cancer and autoimmune diseases where an extended expression window is required." https://www.circio.com/en/circio-enters-in-vivo-cell-therapy-evaluation-agreement-with-acuitas-therapeutics/- ·13 t sitten · MuokattuArticle with Erik Wiklund from today https://themedicinemaker.com/issues/2026/articles/july/surviving-cgts-funding-winter/
Have had faith in this company since before the 1 kr emission. Why shouldn't a Norwegian bio-company make a real breakthrough in gene and cell therapy? Must say that Wiklund appears as a very serious researcher, founder, and business-man who seems enthusiastic and very credible. Incidentally, I have little faith in so-called analysts and experts. I'm no expert myself, but my gut feeling says it could be very good. Have mostly been in profit in the stock market by making my own choices. Happy summer 😀😀 
·13 t sitten10 mill at 16.10 must surely be summer holiday turnover. And a full 2 months since the last visible short. There will probably be more action from August onwards. No one else but possibly a few biotech insiders know anything about a bid. If and when... In the meantime, we can only hope.
·14 t sittenLooks like we have short-term technical resistance at 7.60kr📈 And short-term support at 7.20kr 📉 Just waiting for news…🍺 Will be exciting going forward..😃👍🏼
here I have heard for months that news is coming soon, every week it's supposedly news coming next week.....It will surely be a good atmosphere here when people see that no news came after all and the savings disappeared like dew in the sun....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
92 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenA bit of pure speculation, but I find the timing interesting. Ivan Krivega announced today that he is leaving SonoThera. He has a strong background from SonoThera, Sangamo, BioMarin, and NIH, with a main focus on AAV, gene therapy, and delivery platforms. That made me think of some possible connections. Sangamo and Eli Lilly entered into a collaboration on STAC-BBB, an AAV platform for CNS delivery. Around the same period, Circio announced a fully funded feasibility program with an unnamed top-5 pharmaceutical partner within circVec + AAV for a CNS indication. SonoThera is simultaneously developing RIPPLE™, a non-viral delivery platform based on ultrasound (sonoporation), while Circio is developing circVec, which is a platform for more efficient and long-lasting gene expression. Technologically, these seem more complementary than competitive – one focuses on delivery, the other on expression. Circio has already shown that they want to test circVec with several different delivery systems through collaborations with, among others, Acuitas, GenAssist, TraffikGene, and an unknown top-5 pharma. Therefore, it is not unthinkable that other delivery companies could also be interesting in the long term. Is there a connection between Circio, SonoThera, Sangamo, and Lilly? There is no public information to suggest it. This is purely speculation. But when one sees how much activity is happening around CNS, AAV, circRNA, and new delivery platforms, it seems that many of the same players are moving in the same technological landscape. It will be exciting to see what collaborations emerge in the next 12–24 months. https://www.linkedin.com/posts/ikrivega_today-marks-my-last-day-with-sonothera-share-7483185910994468864-2GIX/?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUIn his time at Sangamo, he was involved with: In vivo genome editing. AAV-based gene therapy. Optimization of gene expression. Delivery of genetic material to organs, including CNS programs. Sangamo's blood-brain barrier capsids which Eli Lilly licensed. He is also listed as an inventor on several Sangamo patents within genome engineering and gene editing. See attached.
- ·10 t sitten · MuokattuNow 3 months ago to the day - 15. April the announcement with Acuitas came. Levitsky stated here translated from the announcement: "Acuitas has developed a state-of-the-art LNP delivery platform specifically to deliver Circio's circVec constructs into T-cells. By combining circVec technology's unparalleled expression durability with the precision of delivery from Acuitas’ LNPs, we aim to establish a new in vivo CAR-T concept for cancer and autoimmune diseases where an extended expression window is required." https://www.circio.com/en/circio-enters-in-vivo-cell-therapy-evaluation-agreement-with-acuitas-therapeutics/
- ·13 t sitten · MuokattuArticle with Erik Wiklund from today https://themedicinemaker.com/issues/2026/articles/july/surviving-cgts-funding-winter/Have had faith in this company since before the 1 kr emission. Why shouldn't a Norwegian bio-company make a real breakthrough in gene and cell therapy? Must say that Wiklund appears as a very serious researcher, founder, and business-man who seems enthusiastic and very credible. Incidentally, I have little faith in so-called analysts and experts. I'm no expert myself, but my gut feeling says it could be very good. Have mostly been in profit in the stock market by making my own choices. Happy summer 😀😀
- ·13 t sitten10 mill at 16.10 must surely be summer holiday turnover. And a full 2 months since the last visible short. There will probably be more action from August onwards. No one else but possibly a few biotech insiders know anything about a bid. If and when... In the meantime, we can only hope.
- ·14 t sittenLooks like we have short-term technical resistance at 7.60kr📈 And short-term support at 7.20kr 📉 Just waiting for news…🍺 Will be exciting going forward..😃👍🏼here I have heard for months that news is coming soon, every week it's supposedly news coming next week.....It will surely be a good atmosphere here when people see that no news came after all and the savings disappeared like dew in the sun....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
92 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenA bit of pure speculation, but I find the timing interesting. Ivan Krivega announced today that he is leaving SonoThera. He has a strong background from SonoThera, Sangamo, BioMarin, and NIH, with a main focus on AAV, gene therapy, and delivery platforms. That made me think of some possible connections. Sangamo and Eli Lilly entered into a collaboration on STAC-BBB, an AAV platform for CNS delivery. Around the same period, Circio announced a fully funded feasibility program with an unnamed top-5 pharmaceutical partner within circVec + AAV for a CNS indication. SonoThera is simultaneously developing RIPPLE™, a non-viral delivery platform based on ultrasound (sonoporation), while Circio is developing circVec, which is a platform for more efficient and long-lasting gene expression. Technologically, these seem more complementary than competitive – one focuses on delivery, the other on expression. Circio has already shown that they want to test circVec with several different delivery systems through collaborations with, among others, Acuitas, GenAssist, TraffikGene, and an unknown top-5 pharma. Therefore, it is not unthinkable that other delivery companies could also be interesting in the long term. Is there a connection between Circio, SonoThera, Sangamo, and Lilly? There is no public information to suggest it. This is purely speculation. But when one sees how much activity is happening around CNS, AAV, circRNA, and new delivery platforms, it seems that many of the same players are moving in the same technological landscape. It will be exciting to see what collaborations emerge in the next 12–24 months. https://www.linkedin.com/posts/ikrivega_today-marks-my-last-day-with-sonothera-share-7483185910994468864-2GIX/?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUIn his time at Sangamo, he was involved with: In vivo genome editing. AAV-based gene therapy. Optimization of gene expression. Delivery of genetic material to organs, including CNS programs. Sangamo's blood-brain barrier capsids which Eli Lilly licensed. He is also listed as an inventor on several Sangamo patents within genome engineering and gene editing. See attached.
- ·10 t sitten · MuokattuNow 3 months ago to the day - 15. April the announcement with Acuitas came. Levitsky stated here translated from the announcement: "Acuitas has developed a state-of-the-art LNP delivery platform specifically to deliver Circio's circVec constructs into T-cells. By combining circVec technology's unparalleled expression durability with the precision of delivery from Acuitas’ LNPs, we aim to establish a new in vivo CAR-T concept for cancer and autoimmune diseases where an extended expression window is required." https://www.circio.com/en/circio-enters-in-vivo-cell-therapy-evaluation-agreement-with-acuitas-therapeutics/
- ·13 t sitten · MuokattuArticle with Erik Wiklund from today https://themedicinemaker.com/issues/2026/articles/july/surviving-cgts-funding-winter/Have had faith in this company since before the 1 kr emission. Why shouldn't a Norwegian bio-company make a real breakthrough in gene and cell therapy? Must say that Wiklund appears as a very serious researcher, founder, and business-man who seems enthusiastic and very credible. Incidentally, I have little faith in so-called analysts and experts. I'm no expert myself, but my gut feeling says it could be very good. Have mostly been in profit in the stock market by making my own choices. Happy summer 😀😀
- ·13 t sitten10 mill at 16.10 must surely be summer holiday turnover. And a full 2 months since the last visible short. There will probably be more action from August onwards. No one else but possibly a few biotech insiders know anything about a bid. If and when... In the meantime, we can only hope.
- ·14 t sittenLooks like we have short-term technical resistance at 7.60kr📈 And short-term support at 7.20kr 📉 Just waiting for news…🍺 Will be exciting going forward..😃👍🏼here I have heard for months that news is coming soon, every week it's supposedly news coming next week.....It will surely be a good atmosphere here when people see that no news came after all and the savings disappeared like dew in the sun....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt